Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Current Deferred Revenue (2020 - 2025)

IDEAYA Biosciences' Current Deferred Revenue history spans 5 years, with the latest figure at $490000.0 for Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $490000.0; the TTM value through Sep 2025 reached $490000.0, changed N/A, while the annual FY2022 figure was $8.6 million, 85.78% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $490000.0 at IDEAYA Biosciences, down from $1.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $77.6 million in Q1 2021 and bottomed at $490000.0 in Q3 2025.
  • The 4-year median for Current Deferred Revenue is $19.9 million (2021), against an average of $25.4 million.
  • The largest annual shift saw Current Deferred Revenue soared 61.98% in 2022 before it tumbled 92.14% in 2023.
  • A 4-year view of Current Deferred Revenue shows it stood at $60.2 million in 2021, then crashed by 85.78% to $8.6 million in 2022, then plummeted by 83.2% to $1.4 million in 2023, then crashed by 65.95% to $490000.0 in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Current Deferred Revenue are $490000.0 (Q3 2025), $1.4 million (Q3 2023), and $2.8 million (Q2 2023).